Myelofibrosis patients in Belgium: disease characteristics
暂无分享,去创建一个
L. Knoops | Z. Berneman | W. Pluymers | A. Kentos | K. Theunissen | D. Bron | Y. Beguin | T. Devos | C. Chatelain | P. Zachée | J. Droogenbroeck | L. Noens | F. Trullemans | P. Mineur | F. Benghiat | H. Demuynck | J. Lemmens | K. Eygen | P. Pierre | Z. Berneman
[1] F. Cervantes. How I treat myelofibrosis. , 2014, Blood.
[2] T. Barbui,et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. , 2013, Blood.
[3] J. Dipersio,et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I , 2013, Haematologica.
[4] L. Knoops,et al. Disease characteristics in Belgian myelofibrosis patients and management guidelines anno 2013 , 2013 .
[5] M. Cazzola,et al. Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence , 2013 .
[6] H. Kantarjian,et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts , 2013, Journal of Hematology & Oncology.
[7] C. Harrison,et al. Treatment and management of myelofibrosis in the era of JAK inhibitors , 2013, Biologics : targets & therapy.
[8] M. Sáez,et al. Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain , 2013, Haematologica.
[9] R. Hoffman,et al. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. , 2013, Blood.
[10] S. Verstovsek,et al. Investigational Janus kinase inhibitors , 2013, Expert opinion on investigational drugs.
[11] R. Laborde,et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis , 2013, Leukemia.
[12] S. Verstovsek,et al. What is next beyond janus kinase 2 inhibitors for primary myelofibrosis? , 2013, Current opinion in hematology.
[13] A. Tefferi,et al. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management , 2013 .
[14] B. Firwana,et al. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms , 2013, Therapeutic advances in hematology.
[15] S. Verstovsek,et al. Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition , 2012, Expert review of hematology.
[16] C. Stiller,et al. Incidence, survival and prevalence of myeloid malignancies in Europe. , 2012, European journal of cancer.
[17] M. Cazzola,et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. , 2012, Blood.
[18] A. Mead,et al. Guideline for the diagnosis and management of myelofibrosis , 2012, British journal of haematology.
[19] R. Hoffman,et al. Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis , 2012, Clinical Cancer Research.
[20] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[21] Francisco Cervantes,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.
[22] G. Barosi,et al. Management of Myeloproliferative Neoplasms: From Academic Guidelines to Clinical Practice , 2012, Current Hematologic Malignancy Reports.
[23] L. To,et al. Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis , 2011 .
[24] Catriona Jamieson,et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Griesshammer,et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] F. Passamonti,et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] T. Petrella,et al. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Côte d’Or (Burgundy, France) , 2011, Haematologica.
[28] M. Cazzola,et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.
[29] N. Kröger,et al. Outcome of transplantation for myelofibrosis. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[30] H. Einsele,et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2009, Blood.
[31] H. Deeg,et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[33] R. Mesa. How I treat symptomatic splenomegaly in patients with myelofibrosis. , 2009, Blood.
[34] O. Abdel-Wahab,et al. Primary myelofibrosis: update on definition, pathogenesis, and treatment. , 2009, Annual review of medicine.
[35] R. Mesa,et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.
[36] D. Rondelli. Allogeneic hematopoietic stem cell transplantation for myelofibrosis , 2008, Haematologica.
[37] G. Barosi,et al. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders , 2008, Leukemia.
[38] J. Sloan,et al. The Burden of Fatigue and Quality of Life in Myeloproliferative Disorders (MPDs): An International Internet Based Survey of 1179 MPD Patients. , 2006 .
[39] R. Mesa,et al. Palliative goals, patient selection, and perioperative platelet management: Outcomes and lessons from 3 decades of splenectomy for myelofibrosiswith myeloid metaplasia at the Mayo Clinic , 2006, Cancer.
[40] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[41] Stefan N. Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.
[42] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[43] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[44] A. Elmaagacli,et al. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis , 2004, Bone Marrow Transplantation.
[45] P. Johansson,et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph‐) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983–99 , 2004, Journal of internal medicine.
[46] A. Tefferi. Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.
[47] J. Sloan,et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) , 2007, Cancer.
[48] H. Møller,et al. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. , 2006, Haematologica.
[49] H. Møller,et al. The incidence and outcome of myeloid malignancies in 2,112 adult patients in South East-England. , 2006 .